eFFECTOR Therapeutics (NASDAQ:EFTR) & AEON Biopharma (NASDAQ:AEON) Financial Contrast

eFFECTOR Therapeutics (NASDAQ:EFTR) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Insider and Institutional Ownership

57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 4.7% of eFFECTOR Therapeutics shares are owned by insiders. Comparatively, 9.4% of AEON Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for eFFECTOR Therapeutics and AEON Biopharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eFFECTOR Therapeutics	0	0	0	0	0.00
AEON Biopharma	0	1	1	1	3.00

Earnings and Valuation

This table compares eFFECTOR Therapeutics and AEON Biopharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eFFECTOR Therapeutics	N/A	N/A	-$35.81 million	($13.08)	0.00
AEON Biopharma	N/A	N/A	-$36.63 million	($5.00)	-0.14

AEON Biopharma is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares eFFECTOR Therapeutics and AEON Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
eFFECTOR Therapeutics	N/A	N/A	N/A
AEON Biopharma	N/A	N/A	-994.63%

Volatility and Risk

eFFECTOR Therapeutics has a beta of 2.41, indicating that its stock price is 141% more volatile than the S&P 500. Comparatively, AEON Biopharma has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500.

Summary

AEON Biopharma beats eFFECTOR Therapeutics on 6 of the 10 factors compared between the two stocks.

About eFFECTOR Therapeutics

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

About AEON Biopharma

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.